Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
BackgroundIntegrating vessels encapsulating tumor clusters (VETC) and microvascular invasion (MVI) (VM hereafter) is potentially useful in risk stratification of hepatocellular carcinoma (HCC). However, noninvasive assessment methods for VM are lacking.PurposeTo investigate the diagnostic performance of tomoelastography in assessing the VM status in HCC.Study TypeRetrospective.PopulationOne hundred sixty‐eight patients with surgically confirmed HCC consisting of 115 training and 53 validation cohorts, divided into negative‐VM and positive‐VM groups with mild or severe‐VMs. Of them, 127 patients completed the follow‐up (median: 26.1 months).Field Strength/Sequence3D multifrequency tomoelastography with a single‐shot spin‐echo echo‐planar imaging sequence, and liver MRI including T1‐weighted in‐phase and opposed‐phase gradient echo (GRE), T2‐weighted turbo spin echo, diffusion‐weighted imaging and dynamic contrast‐enhanced T1‐weighted GRE sequences at 3.0 T.AssessmentShear wave speed (c) and phase angle of the shear modulus (φ) were calculated on tomoelastograms. Imaging features were visually analyzed and clinical features were collected. Conventional models used clinical and imaging features while nomograms combined tomoelastography, clinical and imaging features.Statistical TestsUnivariable and multivariable logistic regression analyses, nomogram, area under the receiver operating characteristic curve (AUC), DeLong test, Kaplan–Meier analysis and log‐rank test. P < 0.05 was considered statistically significant.ResultsTumor‐to‐liver parenchyma ratio of c (cr) and tumor c were independent risk factors for positive‐VM and severe‐VM, respectively. In validation cohort, the nomograms including cr and tumor c performed significantly better than the conventional models for diagnosing positive‐VM (0.84 [95% CI: 0.72–0.93] vs. 0.77 [95% CI: 0.64–0.88]) and severe‐VM (0.86 [95% CI: 0.68–0.96] vs. 0.75 [95% CI: 0.55–0.89]). Patients with estimated positive‐VM (9.3 months)/severe‐VM (9.2 months) based on nomograms had shorter median recurrence‐free survival than those with estimated negative‐VM (>20.0 months)/mild‐VM (18.0 months) in validation cohort.Data ConclusionTomoelastography based‐nomograms showed good performance for noninvasively assessing VM status in patients with HCC.Evidence Level3Technical EfficacyStage 2
BackgroundIntegrating vessels encapsulating tumor clusters (VETC) and microvascular invasion (MVI) (VM hereafter) is potentially useful in risk stratification of hepatocellular carcinoma (HCC). However, noninvasive assessment methods for VM are lacking.PurposeTo investigate the diagnostic performance of tomoelastography in assessing the VM status in HCC.Study TypeRetrospective.PopulationOne hundred sixty‐eight patients with surgically confirmed HCC consisting of 115 training and 53 validation cohorts, divided into negative‐VM and positive‐VM groups with mild or severe‐VMs. Of them, 127 patients completed the follow‐up (median: 26.1 months).Field Strength/Sequence3D multifrequency tomoelastography with a single‐shot spin‐echo echo‐planar imaging sequence, and liver MRI including T1‐weighted in‐phase and opposed‐phase gradient echo (GRE), T2‐weighted turbo spin echo, diffusion‐weighted imaging and dynamic contrast‐enhanced T1‐weighted GRE sequences at 3.0 T.AssessmentShear wave speed (c) and phase angle of the shear modulus (φ) were calculated on tomoelastograms. Imaging features were visually analyzed and clinical features were collected. Conventional models used clinical and imaging features while nomograms combined tomoelastography, clinical and imaging features.Statistical TestsUnivariable and multivariable logistic regression analyses, nomogram, area under the receiver operating characteristic curve (AUC), DeLong test, Kaplan–Meier analysis and log‐rank test. P < 0.05 was considered statistically significant.ResultsTumor‐to‐liver parenchyma ratio of c (cr) and tumor c were independent risk factors for positive‐VM and severe‐VM, respectively. In validation cohort, the nomograms including cr and tumor c performed significantly better than the conventional models for diagnosing positive‐VM (0.84 [95% CI: 0.72–0.93] vs. 0.77 [95% CI: 0.64–0.88]) and severe‐VM (0.86 [95% CI: 0.68–0.96] vs. 0.75 [95% CI: 0.55–0.89]). Patients with estimated positive‐VM (9.3 months)/severe‐VM (9.2 months) based on nomograms had shorter median recurrence‐free survival than those with estimated negative‐VM (>20.0 months)/mild‐VM (18.0 months) in validation cohort.Data ConclusionTomoelastography based‐nomograms showed good performance for noninvasively assessing VM status in patients with HCC.Evidence Level3Technical EfficacyStage 2
Background: Microvascular invasion (MVI) is an independent risk factor of poor prognosis in hepatocellular carcinoma (HCC) and can be used to guide the diagnosis and treatment of HCC. The immune system serves as an integral role in the incidence and progression of HCC. However, the molecular biology correlation between MVI and tumor immunity and the value of combining the two parameters to predict patient prognosis and HCC response to treatment remain to be evaluated. Results: In this study, we used univariate Cox regression analysis and least absolute shrinkage and selection operator (LASSO) Cox analysis to establish the MVI and immune-related gene index (MIRGPI) including eight genes. We demonstrated that the MIRGPI was an independent risk factor in predicting the prognosis of HCC. Subsequently, our research established a nomogram model combining pathologic characteristics and verified its good clinical application value. In addition, our study found that the TP53 gene had a higher mutation frequency and a lower degree of immune infiltration in the high-risk group. The low-risk group had higher sensitivity to immunotherapy, sorafenib, and TACE treatment, and the high-risk group had higher sensitivity to common chemotherapeutic agents. Finally, SEMA3C was found to facilitate the proliferation, migration and invasive ability of HCC by in vitro and in vivo experiments, and its mechanism may be associated with the activation of the NF-Κb/EMT signaling pathway. Conclusions: In summary, the MIRGPI signature we developed is a reliable marker for the prediction of prognosis and treatment response, and is important for the prognostic assessment and individualized treatment of HCC. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-024-78467-3.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.